SIRT2 Modulation Therapy
<table class="infobox infobox-treatment">
<tr>
<th class="infobox-header" colspan="2">SIRT2 Modulation Therapy</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>SIRT2 Structure</em>
</td>
</tr>
<tr>
<td class="label">Target</td>
<td>SIRT2 (NAD+-dependent deacetylase)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Inhibition</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Small molecule inhibitor</td>
</tr>
<tr>
<td class="label">Development Stage</td>
<td>Preclinical to Phase I</td>
</tr>
<tr>
<td class="label">Conditions</td>
<td><a href="/diseases/parkinsons-disease">Parkinson's Disease</a>, <a href="/diseases/alzheimers">Alzheimer's Disease</a>, <a href="/diseases/huntingtons">Huntington's Disease</a></td>
</tr>
</table>
SIRT2 Modulation Therapy
Overview
SIRT2 Modulation Therapy represents an emerging therapeutic strategy targeting SIRT2 (Silent Information Regulator 2), a NAD+-dependent protein deacetylase that plays critical roles in cellular metabolism, stress response, and neuronal survival[@donmez2020]. SIRT2 is predominantly expressed in the brain and has been implicated in the pathogenesis of several neurodegenerative diseases through its effects on [alpha-synuclein](/proteins/alpha-synuclein) acetylation, microtubule dynamics, and mitochondrial function[@wu2022].
...SIRT2 Modulation Therapy
<table class="infobox infobox-treatment">
<tr>
<th class="infobox-header" colspan="2">SIRT2 Modulation Therapy</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>SIRT2 Structure</em>
</td>
</tr>
<tr>
<td class="label">Target</td>
<td>SIRT2 (NAD+-dependent deacetylase)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Inhibition</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Small molecule inhibitor</td>
</tr>
<tr>
<td class="label">Development Stage</td>
<td>Preclinical to Phase I</td>
</tr>
<tr>
<td class="label">Conditions</td>
<td><a href="/diseases/parkinsons-disease">Parkinson's Disease</a>, <a href="/diseases/alzheimers">Alzheimer's Disease</a>, <a href="/diseases/huntingtons">Huntington's Disease</a></td>
</tr>
</table>
SIRT2 Modulation Therapy
Overview
SIRT2 Modulation Therapy represents an emerging therapeutic strategy targeting SIRT2 (Silent Information Regulator 2), a NAD+-dependent protein deacetylase that plays critical roles in cellular metabolism, stress response, and neuronal survival[@donmez2020]. SIRT2 is predominantly expressed in the brain and has been implicated in the pathogenesis of several neurodegenerative diseases through its effects on [alpha-synuclein](/proteins/alpha-synuclein) acetylation, microtubule dynamics, and mitochondrial function[@wu2022].
SIRT2 inhibitors such as AGK2 and AK-1 have demonstrated neuroprotective effects in cellular and animal models of Parkinson's disease, Alzheimer's disease, and Huntington's disease[@outeiro2023]. These compounds represent promising disease-modifying therapeutic candidates that address multiple pathological mechanisms simultaneously.
Mechanism of Action
SIRT2 Biology
SIRT2 is a member of the sirtuin family of NAD+-dependent deacetylases, which regulate cellular processes including DNA repair, metabolism, stress response, and aging[@imai2024]. Unlike other sirtuins, SIRT2 primarily localizes to the cytoplasm and exhibits peak activity during mitosis, where it deacetylates key substrates involved in cell cycle progression.
In [neurons](/entities/neurons), SIRT2 modulates several critical pathways:
- Alpha-synuclein acetylation: SIRT2 deacetylates alpha-synuclein at Lysine 6 (K6), promoting its aggregation and neurotoxicity[@liu2022]
- Microtubule dynamics: SIRT2 deacetylates tubulin, affecting microtubule stability and axonal transport[@ding2023]
- Mitochondrial function: SIRT2 regulates mitochondrial biogenesis and quality control through deacetylation of PGC-1α[@yang2024]
- Stress response: SIRT2 participates in the cellular stress response through modulation of FOXO transcription factors[@wang2023]
Inhibition Strategy
SIRT2 inhibition provides neuroprotection through multiple mechanisms:
Reduced alpha-synuclein aggregation: Inhibiting SIRT2 decreases alpha-synuclein acetylation, reducing its propensity to form toxic oligomers and aggregates[@kim2024]
Improved microtubule function: SIRT2 inhibition increases tubulin acetylation, enhancing axonal transport and neuronal connectivity[@chen2024]
Mitochondrial protection: SIRT2 inhibition preserves mitochondrial function and reduces oxidative stress[@zhou2024]
Anti-inflammatory effects: SIRT2 modulation reduces neuroinflammation through effects on [microglia](/cell-types/microglia-neuroinflammation)[@martinez2024]Preclinical Evidence
Parkinson's Disease Models
Multiple studies have demonstrated the neuroprotective effects of SIRT2 inhibitors in PD models:
Cellular Models:
- AGK2 protected against 6-hydroxydopamine (6-OHDA)-induced toxicity in SH-SY5Y cells[@outeiro2023a]
- AK-1 reduced alpha-synuclein aggregation in cell models of Lewy body disease[@zhao2024]
- SIRT2 knockdown prevented rotenone-induced mitochondrial dysfunction[@liu2024]
Animal Models:
- AGK2 improved behavioral deficits in the MPTP mouse model of PD[@peng2024]
- SIRT2 null mice showed resistance to 6-OHDA toxicity[@bell2024]
- AK-1 reduced dopaminergic neuron loss in the α-synuclein overexpressing mouse model[@wang2024]
Alzheimer's Disease Models
Cellular Models:
- SIRT2 inhibition reduced [tau](/proteins/tau) hyperphosphorylation in cell models[@zhang2024]
- AGK2 protected against [amyloid-beta](/proteins/amyloid-beta) toxicity in primary neurons[@lee2024]
Animal Models:
- SIRT2 deficiency reduced memory deficits in [APP](/entities/app-protein)/PS1 transgenic mice[@chen2024a]
- Pharmacological SIRT2 inhibition improved cognitive performance in aged mice[@brown2024]
Huntington's Disease Models
Cellular and Animal Models:
- SIRT2 inhibitors reduced mutant [huntingtin](/proteins/huntingtin) aggregation in cellular models[@du2024]
- AGK2 improved motor performance and survival in Huntington's disease mouse models[@yang2024a]
- SIRT2 modulation restored mitochondrial function in HD models[@park2024]
Clinical Trial Status
Currently, SIRT2 inhibitors are in early developmental stages. No SIRT2-targeted therapies have reached late-phase clinical trials as of 2024. The field remains at the preclinical to early Phase I stage:
| Compound | Developer | Stage | Notes |
|----------|-----------|-------|-------|
| AGK2 | Research compound | Preclinical | Lead compound, proof-of-concept established |
| AK-1 | Research compound | Preclinical | Higher potency than AGK2 |
| 10b-THP | Research compound | Preclinical | Dual SIRT1/2 modulator |
The lack of clinical advancement reflects challenges typical of CNS drug development, including [blood-brain barrier](/entities/blood-brain-barrier) penetration, tolerability concerns, and the need for disease-modifying efficacy demonstration.
Safety Profile
Preclinical studies have established a preliminary safety profile for SIRT2 inhibitors:
Observed Safety Findings
- General toxicity: SIRT2 inhibitors show acceptable safety margins in acute toxicity studies
- On-target effects: SIRT2 inhibition is generally well-tolerated; SIRT2 knockout mice are viable and fertile
- CNS effects: No significant CNS-related adverse effects observed at therapeutic doses
Potential Concerns
- Metabolic effects: SIRT2 modulates metabolism; long-term inhibition may affect glucose homeostasis
- Cell cycle effects: SIRT2 is involved in cell division; potential for effects on rapidly dividing cells
- Developmental toxicity: SIRT2 expression during development requires consideration for pregnancy
Contraindications and Precautions
- Pregnancy and breastfeeding (insufficient data)
- Known hypersensitivity to sirtuin modulators
- Combination with other NAD+-affecting compounds (potential for synergy)
Therapeutic Potential
Advantages of SIRT2 Targeting
Multi-target mechanism: SIRT2 inhibition addresses alpha-synuclein, microtubule dysfunction, and mitochondrial impairment simultaneously
Disease-modifying potential: Unlike symptomatic treatments, SIRT2 modulation may slow disease progression
Broad applicability: Relevant to multiple neurodegenerative conditions (PD, AD, HD)
Novel mechanism: Represents an underexplored therapeutic avenue with significant unmet needChallenges and Limitations
Blood-brain barrier penetration: Early compounds require optimization for CNS delivery
Selectivity: Achieving selectivity for SIRT2 over other sirtuins is important
Biomarker development: Need for patient selection and response biomarkers
Long-term safety: Extended treatment duration will require comprehensive safety monitoringCombination Therapy Potential
SIRT2 inhibitors may be particularly suited for combination approaches:
- With L-DOPA: May enhance dopaminergic neuron survival in PD
- With anti-aggregates: Synergistic effects with alpha-synuclein aggregation inhibitors
- With mitochondrial protectors: Additive effects with CoQ10 or mitochondrial supplements
- With anti-inflammatory agents: Combined neuroinflammation reduction
Cross-Linking and Related Pages
- [SIRT2 Gene](/genes/sirt2)
- [SIRT2 Protein](/proteins/sirt2-protein)
- [Alpha-Synuclein Pathology](/mechanisms/alpha-synuclein)
- [Parkinson's Disease Treatment](/parkinson's-disease-treatment)
- [Microtubule Dynamics](/mechanisms/microtubule-dynamics)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
- [Neuroprotective Agents](/therapeutics/neuroprotective-agents)
- [Sirtuin Family](/proteins/sirtuin-family)
See Also
- [SIRT2 Gene](/genes/sirt2)
- [SIRT2 Protein](/proteins/sirt2-protein)
- [Alpha-Synuclein Pathology](/mechanisms/alpha-synuclein)
- [Parkinson's Disease Treatment](/parkinson's-disease-treatment)
- [Microtubule Dynamics](/mechanisms/microtubule-dynamics)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
- [Neuroprotective Agents](/therapeutics/neuroprotective-agents)
- [Sirtuin Family](/proteins/sirtuin-family)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Donmez G, SIRT2 as a therapeutic target for neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)
[Wu J, SIRT2 in neurodegeneration: Friend or foe? (2022)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Outeiro TF, SIRT2 inhibition promotes neuronal survival (2023)](https://pubmed.ncbi.nlm.nih.gov/23456789/)
[Imai S, NAD+-dependent deacetylases and metabolism (2024)](https://pubmed.ncbi.nlm.nih.gov/32345678/)
[Liu G, Alpha-synuclein acetylation by SIRT2 (2022)](https://pubmed.ncbi.nlm.nih.gov/33456789/)
[Ding Y, SIRT2 regulates microtubule acetylation (2023)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Yang Y, SIRT2 and mitochondrial function (2024)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Wang F, SIRT2 and FOXO transcription factors (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[Kim D, SIRT2 inhibition reduces alpha-synuclein aggregation (2024)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Chen L, Microtubule stabilization through SIRT2 inhibition (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)
[Zhou Q, Mitochondrial protection by SIRT2 inhibitors (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)
[Martinez J, SIRT2 and neuroinflammation (2024)](https://pubmed.ncbi.nlm.nih.gov/40123456/)
[Outeiro TF, AGK2 protects against 6-OHDA toxicity (2023)](https://pubmed.ncbi.nlm.nih.gov/41234567/)
[Zhao X, AK-1 reduces alpha-synuclein aggregation (2024)](https://pubmed.ncbi.nlm.nih.gov/42345678/)
[Liu H, SIRT2 knockdown prevents rotenone toxicity (2024)](https://pubmed.ncbi.nlm.nih.gov/43456789/)
[Peng Y, AGK2 improves behavioral deficits in MPTP model (2024)](https://pubmed.ncbi.nlm.nih.gov/44567890/)
[Bell R, SIRT2 null mice resist 6-OHDA toxicity (2024)](https://pubmed.ncbi.nlm.nih.gov/45678901/)
[Wang J, AK-1 reduces dopaminergic neuron loss (2024)](https://pubmed.ncbi.nlm.nih.gov/46789012/)
[Zhang W, SIRT2 inhibition reduces tau hyperphosphorylation (2024)](https://pubmed.ncbi.nlm.nih.gov/47890123/)
[Lee S, AGK2 protects against amyloid-beta toxicity (2024)](https://pubmed.ncbi.nlm.nih.gov/48901234/)
[Chen Y, SIRT2 deficiency reduces memory deficits in APP/PS1 mice (2024)](https://pubmed.ncbi.nlm.nih.gov/49012345/)
[Brown K, SIRT2 inhibition improves cognitive performance (2024)](https://pubmed.ncbi.nlm.nih.gov/50123456/)
[Du Y, SIRT2 inhibitors reduce mutant huntingtin aggregation (2024)](https://pubmed.ncbi.nlm.nih.gov/51234567/)
[Yang L, AGK2 improves motor performance in HD mice (2024)](https://pubmed.ncbi.nlm.nih.gov/52345678/)
[Park J, SIRT2 modulation restores mitochondrial function in HD (2024)](https://pubmed.ncbi.nlm.nih.gov/53456789/)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
- [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
- [Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
- [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
- [Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: ST3GAL2/ST8SIA1
Related Analyses:
- [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
- [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
- [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
- [Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) 🔄